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The immune checkpoint blockade is a novel approach of cancer therapy, which 
markedly enhanced treatment efficacy of several cancer types. However, the frequency 
of cancer patients non-responding to this treatment is high. Establishment of predictive 
markers to distinguish patients suitable for the immune checkpoint blockade would 
enhance the number of patients receiving benefit from the therapy. This dissertation thesis 
focuses on the enhancement of efficacy of immune checkpoint inhibitors (ICIs) and 
predictive markers in experimental models of mouse tumours induced by TC-1 and TC-
1/A9 cell lines and its clones with deactivation of interferon (IFN)-γ signalling (TC-
1/dIfngr1 and TC-1/A9/dIfngr1), or CD80 molecule (TC-1/dCD80-1). IFN-γ is presumed 
to be the main inducer of programmed death ligand 1 (PD-L1) and a major 
histocompatibility complex I (MHC-I). Moreover, PD-L1 expression may predict 
sensitivity to PD-1/PD-L1 blockade. Non-functional IFN-γ signalling or downregulated 
MHC-I expression has been associated with resistance to ICIs in some patients. We found 
that IFNs type I (IFN-α and IFN-β) induced the expression of PD-L1 and MHC-I on TC-
1/A9/dIfngr1 tumour cells with reversible downregulation of both molecules. We also 
showed that deactivation of IFN-γ signalling in TC-1/A9 cells was not a contraindication 
to PD-1/PD-L1 blockade combined with DNA vaccination. As TC-1-induced tumours 
were not sensitive to PD-L1 blockade, we next investigated the impact of CD80 expressed 
in tumour cells on the efficacy of ICIs and the tumour microenvironment. Although the 
CD80 deactivation in tumour cells did not induce the efficacy of anti-PD-L1 antibody, it 
considerably promoted the efficacy of anti-CTLA-4 antibody. Moreover, TC-1/dCD80-1 
cells were more immunogenic than the TC-1 cell line. Therefore, CD80 molecule should 
be assessed as a predictive marker for cancer treatment by CTLA-4 blockade and as a 
possible target for the development of tumour cell-specific cancer therapy. Besides the 
major projects, experimental combined therapy of tumours with reversible 
downregulation of MHC-I and development of mouse oncogenic cell line with 
irreversible downregulation of MHC-I by deactivation of beta-2-microglobulin (B2m) are 
included in the thesis. Altogether, we developed clinically relevant models of mouse 
tumours with deactivated IFNGR1, CD80, and B2m and used them for enhancement of 





Blokování kontrolních bodů imunitních reakcí je novým terapeutickým přístupem 
v léčbě nádorů, který značně zvýšil účinnost léčby různých typů nádorů. Avšak podíl 
pacientů s nádory neodpovídajících na tuto léčbu je vysoký. Zavedení predikčních znaků 
pro rozlišení pacientů vhodných pro léčbu blokováním kontrolních bodů by mohlo zvýšit 
počet pacientů, kteří by měli z této léčby užitek. Tato disertační práce je zaměřena na 
zvýšení účinnosti inhibitorů kontrolních bodů imunitních reakcí (ICIs) a na predikční 
znaky s využitím experimentálních modelů myších nádorů vyvolaných buněčnými 
liniemi TC-1 a TC-1/A9 a jejich klony s deaktivací signalizace interferonu (IFN)-γ (TC-
1/dIfngr1 a TC-1/A9/dIfngr1) nebo molekuly CD80 (TC-1/dCD80-1). IFN-γ je 
považován za hlavní cytokin zvyšující expresi ligandu programované buněčné smrti 1 
(PD-L1) a hlavního histokompatibilního komplexu I (MHC-I). Exprese PD-L1 může 
předpovídat citlivost k blokování PD-1/PD-L1. Nefunkční signalizace IFN-γ nebo 
snížená exprese MHC-I u některých pacientů souvisela s rezistencí k ICIs. Zjistili jsme, 
že IFN I. typu (IFN-α a IFN-β) zvyšují expresi PD-L1 a MHC-I na nádorových buňkách 
TC-1/A9/dIfngr1 s reverzibilně sníženou expresí obou molekul. Také jsme ukázali, že 
deaktivace signalizace IFN-γ v buňkách TC-1/A9 nebyla kontraindikací pro blokování 
PD-1/PD-L1 v kombinaci s DNA vakcinací. Protože nádory vyvolané buňkami TC-1 
nebyly citlivé na blokování PD-L1, následně jsme vyšetřovali vliv molekuly CD80, 
produkované v nádorových buňkách, na účinnost ICIs a na nádorové mikroprostředí. 
Přesto, že deaktivace CD80 v nádorových buňkách nezvýšila účinnost protilátky anti-PD-
L1, významně podpořila účinnost protilátky anti-CTLA-4. Buňky TC-1/dCD80-1 byly 
více imunogenní než buněčná linie TC-1. Proto by měl být posouzen význam molekuly 
CD80 jako predikčního znaku pro léčbu nádorů blokováním CTLA-4 a také jako možný 
cíl pro vývoj terapie proti nádorovým buňkám. Kromě hlavních projektů je v této práci 
zahrnuta experimentální kombinovaná terapie nádorů s reverzibilním snížením MHC-I a 
vývoj myší onkogenní buněčné linie s ireverzibilně sníženou expresí MHC-I 
prostřednictvím deaktivace beta-2-mikroglobulinu (B2m). Vyvinuli jsme klinicky 
významné myší modely nádorů s deaktivací IFNGR1, CD80 a B2m a využili je pro 





1.1. Immune checkpoints 
Co-stimulatory and co-inhibitory molecules, defined as immune checkpoints, 
tightly regulate immune reactions in order to maintain homeostasis of the host and to 
avoid immunopathology (1, 2). The immune checkpoints were originally studied in T 
cells. Besides the 1st signal, which naïve T cells receive from the T cell receptor (TCR) 
after recognition of antigen presented on the major histocompatibility complex (MHC), 
co-stimulatory and co-inhibitory receptors provide the 2nd signal in antigen-independent 
manner (3, 4). Co-stimulatory receptors (such as cluster of differentiation (CD)28, CD80, 
CD86, inducible T cell costimulatory (ICOS), glucocorticoid-induced tumour necrosis 
factor receptor (GITR) and many others) support T cell activation, effector functions and 
survival (5, 6). On the contrary, co-inhibitory receptors and their corresponding ligands 
promote the state of unresponsiveness to antigenic stimulation. Overexpression of co-
inhibitory molecules is one of the major characteristics of T cell exhaustion, which can 
be induced by persistent antigenic stimulation due to a chronic infection or cancer (7). 
Expression of co-inhibitory receptors alternates during the T cell activation and 
differentiation (8). Naïve T cells express a high level of B and T lymphocyte attenuator 
(BTLA) and T cell immunoglobulin mucin-3 (Tim-3) is detectable during this early stage 
too (9). Additional co-inhibitory receptors, such as (cytotoxic T lymphocyte antigen 4 
(CTLA-4), programmed death 1 (PD-1), lymphocyte-activation gene 3 (Lag-3), CD244, 
T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based 
inhibition motif  domains (TIGIT) and killer cell lectin-like receptor subfamily G member 
1 (KLRG-1)), are upregulated following antigenic stimulation (10, 11). Majority of the 
terminally differentiated effector T cells undergo apoptosis after clearance of antigen, 
whereas long-lived memory T cells maintain the response after the secondary exposure 
to antigen (12, 13). Immune checkpoint molecules are important regulators of T cell 
memory establishment. Expression of various immune checkpoints is specific for distinct 
types of memory T cells, such as relatively high expression of immune checkpoints on 
effector memory T cells in comparison with central memory T cells (10). Interestingly, 
some immune checkpoints, such as PD-1, inhibit CD8+ T cell differentiation into memory 




The firstly discovered immune checkpoint was CTLA-4, a type I transmembrane 
receptor of the immunoglobulin family, expressed by T cells (15).  CTLA-4 competes 
with CD28 for binding to the ligands CD80 and CD86 in order to inhibit activation of 
naïve T cells (16–18). The affinity of CTLA-4 for CD80 and CD86 binding is approx. ten 
times higher than that of CD28 (18). The study also shows that CD80 and CTLA-4 
expression increases in activated antigen presenting cells (APCs) and T cells, 
respectively, whereas the expression of CD86 and CD28 is constitutive. CD80 is therefore 
considered to be the primary ligand of CTLA-4, while CD86 predominantly interacts with 
CD28 (18, 19). Expression of CTLA-4 varies in different T cell subsets. CTLA-4 is 
expressed especially on activated CD4+ T cells and to a lesser extent on CD8+ T cells 
(20). CTLA-4 mediated immunosuppression is one of the major effector mechanisms of 
regulatory T (Treg) cells, which constitutively express high level of this molecule (21, 
22). The essential role of CTLA-4 in Treg mediated immunosuppression has been 
determined by Treg-specific CTLA-4 deactivation (23). In that study, CTLA-4- Treg cells 
were unable to maintain self-tolerance and Treg specific CTLA-4 deactivation promoted 
anti-tumour immunity. 
Furthermore, one of the most frequently studied immune checkpoints is PD-1, a 
type I transmembrane receptor and a member of the CD28/CTLA-4 family of 
immunoglobulin receptors (24). The PD-1 gene was originally studied in apoptotic cell 
lines and in mouse thymocytes (25). Function of this molecule was determined in a PD-
1 deficient mouse model (26). The animals developed severe lupus-like autoimmune 
disease, which indicated the immunosuppressive role of PD-1. The PD-1 protein structure 
consists of N-terminal Ig-like variable domain, a transmembrane region, and an 
intracellular tail (27). Binding of ligand to PD-1 through the variable domain triggers 
phosphorylation of immunoreceptor tyrosine-based inhibition motif and immunoreceptor 
tyrosine-based switch motif on the PD-1 intracellular domain and association with 
sarcoma homology 2 domain-containing protein (SHP) 1 and SHP2 tyrosine phosphatases 
(27–29). Subsequently, SHP1/2 interfere with TCR and CD28 signalling pathways, 
suppress T cell functions and promote apoptosis (30–32).  
PD-1 is expressed especially on activated and effector memory T cells, Treg cells, 
and natural killer (NK) T cells, and to some extent on B cells and NK cells (10, 33–35). 
MHC-I restricted cytotoxic CD8+ T cells are presumably the main target of PD-




some tumours with downregulated MHC-I expression is mediated by NK cells, 
independently of CD8+ T cells, and such tumours may also be sensitive to the PD-1/PD-
L1 blockade (37). However, the direct effect of PD-1 blockade on NK cell effector 
functions remains unclear (38). Moreover,  recent study has revealed an essential role of 
myeloid cells in PD-1 mediated tumour protection (39). Specific deactivation of PD-1 in 
myeloid cells resulted in enhanced effector functions of monocytes, macrophages, and 
dendritic cells (DCs), reduced frequency of myeloid-derived suppressor cells (MDSCs), 
and elevated frequency of effector memory T cells with improved anti-tumour effector 
functions, although PD-1 expression on lymphoid cells was preserved.  
PD-1 interacts with PD-L1 (Fig. 1) as well as PD-L2 (24, 40). Tumour cells and 
several types of tumour infiltrating cells, such as T cells, B cells, NK cells, macrophages, 
and DCs, may express PD-L1 and inhibit anti-cancer immune response (41–43). PD-L2 
is expressed on stimulated macrophages and DCs, or B cells (44–46). Unlike PD-L1, the 
contribution of PD-L2 in the immune response is controversial. In some settings, PD-L2 
acts as a co-stimulatory molecule, independent of PD-1, and inhibits tumour growth (45). 
PD-L1 expression on tumour cells and/or host cells promotes tumour growth of 
some tumour types (47–51). Importance of PD-L1 expression on host cells in the 
inhibition of anti-tumour immunity was identified in B16 melanoma (47). Moreover, PD-
L1 expression on myeloid cells was found to be essential for response to PD-1/PD-L1 
blockade in MC38-, A20-, and E.G7-induced tumours (51). Another study showed that 
MC38 tumour cells as well as host cells inhibit T cell cytotoxicity and contribute to 
Figure 1: Molecular structure of PD-1/PD-L1 complex. The PD-1 domains are shown in 




tumour escape from immune surveillance (49, 50). Therefore, PD-L1 expression on 
tumour cells and host cells may be predictive in the selection of patients suitable for PD-
1/PD-L1 blockade. 
PD-L1 overexpression is a frequently occurring immune escape mechanism in 
tumours. 9p24.1 amplification, enhancement of PD-L1 transcription, or increased 
messenger ribonucleic acid (mRNA) stability due to disruption of the PD-L1 mRNA three 
prime untranslated region upregulate PD-L1 expression (52–54). PD-L1 expression may 
also be enhanced by constitutive activation of some signalling pathways in tumours, such 
as mitogen-activated protein kinase kinase/extracellular signal-regulated kinase, 
phosphatidylinositol 3-kinase/protein kinase B, Janus kinase (JAK)/signal transducer and 
activator of transcription proteins (STAT), neurogenic locus notch homolog protein 
3/mammalian target of rapamycin, or microRNA-200/zinc-finger E-box-binding 
homeobox 1 (55–58). Some transcription factors have been reported to induce PD-L1 
expression, for example, hypoxia-inducible factor 2α or STAT3 (59, 60). Furthermore, 
PD-L1 upregulation in cancer is associated with viruses, such as Epstein-Barr virus 
(EBV) and hepatitis B virus, and some bacteria, such as Helicobacter pylori (61–64). 
However, the relationship between PD-L1 and viruses is not uniform in various studies 
(65–67). Significantly upregulated PD-L1 expression was associated with lymphocyte 
infiltration in tumours and interferon (IFN)-γ expression in some human papillomavirus 
(HPV)+ head and neck squamous cell carcinoma (HNSCC) patients (66). On the contrary, 
another study of HNSCC reported that HPV infection correlated with methylation of PD-
L1 promotor and silenced transcription of the corresponding gene (65). In conjunctival 
squamous cell carcinoma (SCC), PD-L1 expression did not correlate with HPV status 
(67).  
Several studies evaluated PD-L1 as a prognostic marker in various cancer types. 
For instance, upregulated PD-L1 implied reduced overall survival (OS) in breast cancer 
(68). The study showed that PD-L1 expression was associated with increased tumour size, 
metastasis into lymph nodes, and oestrogen receptor negativity. Moreover, genetic 
alteration of 9p24.1 and PD-L1 upregulation in hepatocellular carcinoma correlated with 
poor outcome of patients (69). On the contrary, PD-L1 in melanoma did not predict the 
prognosis, although upregulation of PD-L1 correlated with the absence of metastasis in 




1.2. Cytokines in the tumour microenvironment 
Cytokines are indispensable regulators of immune reactions and modulate anti-
cancer immune response. One of the most frequently studied cytokines in cancer is IFN-
γ, a type II IFN occurring in the form of a homodimer, which was discovered in activated 
human leucocytes (71). This cytokine is produced in tumours mainly by stimulated T 
cells, innate lymphoid cells (ILC)1, NK cells, and NKT cells (72–74). IFN-γ receptor 
(IFNGR) comprises two IFNGR1 and two IFNGR2 subunits. The IFNGR recruits non-
receptor tyrosine kinases JAK1 and JAK2 upon binding IFN-γ that activate transcription 
factors STAT1 or STAT3 (75, 76). IFN-γ induces the expression of IFN stimulated genes 
(ISGs) in tumour cells as well as host cells and affects tumour growth (77). So far, 124 
proteins of IFN-γ signalling pathway have been described (78, 79).  
IFN-γ is a pleiotropic cytokine that can regulate multiple mechanisms in tumours, 
for instance, antigen presentation, cell infiltration, cell cycle, metabolism, invasiveness, 
and immunosuppression (78). IFN-γ induces MHC-I expression and production of 
chemokines with anti-tumour functions such as chemokine (C-X-C motif) ligand (CXCL) 
9, CXCL10 and CXCL11 (80, 81). IFN-γ can downregulate PD-1 and act in a synergy 
with immune checkpoint blockade (82). Furthermore, IFN-γ contributes to the 
polarization of macrophages into anti-tumour M1 phenotype (83). This cytokine may also 
switch immunosuppressive tumour associated macrophages (TAMs) to M1 macrophages, 
which express inducible nitric oxide synthase (iNOS) and produce nitric oxide (NO) (84).  
Besides the immunostimulatory function of IFN-γ, this cytokine promotes the 
expression of immunosuppressive molecules, such as PD-L1 or indolamine 2,3-
dioxygenase (IDO). IFN-γ upregulates the PD-L1 on tumour cells and host cells and PD-
L1 upregulation was also observed on exosomes derived from tumour cells (85, 86). 
Efficiency of IFN-γ to stimulate PD-L1 was even enhanced in triple negative breast 
cancer (TNBC) by amplification of 9p24.1 chromosome (87). However, contradictory 
effect of IFN-γ signalling on anti-tumour immune response has been determined in 
tumour cells in comparison with immune cells (77). IFN-γ promoted PD-L1 expression 
on colorectal and melanoma cancer cells, while it simultaneously stimulated effector 
functions of immune cells in that study. Deactivation of IFN-γ signalling in tumour cells 
resulted in increased accumulation of T cells, maturation of NK/ILC1 cells, and 




Even though IFN-γ is considered to be the major cytokine inducing MHC-I and 
PD-L1, other cytokines may have similar effect. A broad range of cytokines induce MHC-
I expression, such as IFN-α, IFN-β, tumour necrosis factor (TNF)-α, interleukin (IL)-1α, 
or IL-27 (80, 88–90). Furthermore, IFN-α, IFN-β, IL-1α, IL-1β, IL-27, CCL2, and 
granulocyte-macrophage colony stimulating factor (GM-CSF) can induce the PD-L1 
expression (80, 86, 91–95). Some cytokines (for instance, TNF-α, epidermal growth 
factor (EGF), and IL-6) regulate post-translational modifications of PD-L1 and stabilize 
the molecule by inhibition of proteasomal degradation (96–98).  
1.3. Immune checkpoint inhibitors 
Recent discovery of the immune checkpoints and approval of immune checkpoint 
inhibitors (ICIs) was a real breakthrough in cancer therapy because it prolonged survival 
of many patients with different tumour types (99). In 2018, James Allison and Tasuku 
Honjo were awarded the Nobel Prize in Physiology and Medicine for their discovery of  
CTLA-4 and PD-1 and the development of ICIs (100). The first ICI, a monoclonal 
antibody blocking CTLA-4 (ipilimumab), was approved by FDA in 2011 for treatment of 
malignant melanoma (101). In 2014, first antibodies targeting PD-1 (pembrolizumab and 
nivolumab) were approved for the treatment of metastatic melanoma and approvals for 
additional types of cancer (such as non-small-cell lung carcinoma (NSCLC), renal cell 
carcinoma (RCC), and head and neck carcinoma) were approved later (102–104). 
Moreover, another anti-PD-1 antibody (cemiplimab) was approved in 2018 for treatment 
of cutaneous SCC (105). Furthermore, PD-L1 blockade has been found effective in anti-
cancer therapy. In 2016, the first anti-PD-L1 monoclonal antibody (atezolizumab) was 
approved for the treatment of bladder cancer, NSCLC, and triple-negative breast cancer 
(106–108). Additional approvals of new anti-PD-L1 antibodies (avelumab and 
durvalumab) followed later (109, 110). 
1.4. Mechanisms of tumour resistance to immune checkpoint inhibitors  
Successful immunotherapy promotes recognition of tumour cells by the immune 
system and tumour elimination (111). Although the immune checkpoint blockade was a 
breakthrough in cancer therapy, many cancer patients are resistant to ICIs (112, 113). 
Patients with primary (innate) resistance are completely non-sensitive to the therapy and 
patients with secondary (acquired) resistance initially respond to the treatment and 




and the cancer therapy shape characteristics of tumours and may result in the tumour 
elimination, or evasion of the immune system and therapy (115–117).  
The tumour microenvironment affects the therapeutic outcome of immune 
checkpoint blockade (118). Distinct types of tumours have been characterised as “cold” 
or “hot” based on the level of tumour infiltration by immune cells and anti-cancer immune 
response. The cold tumours are often resistant to immunotherapy and therefore the 
development of combined therapy to switch cold tumours into hot is a challenging issue 
(119).  Cold tumours are deficient in activated immune cells owing to the absence of 
danger signals, insufficient tumour antigen presentation, or inability of immune cells to 
infiltrate the tumour. Immune cells accumulate in hot tumours, although persistent 
stimulation with tumour antigens leads to exhaustion of T cells and to strengthening of 
suppressive mechanisms in the tumour microenvironment. The hot tumours are especially 
sensitive to immune checkpoint blockade (120, 121). ICIs may restore the activation of 
exhausted T cells accumulated in hot tumours and promote tumour regression. 
 Abrogation of tumour antigen presentation due to defects in the antigen-
processing machinery or downregulation of MHC-I expression frequently occurs in 
patients resistant to ICIs (122–125). Moreover, primary as well as secondary resistance 
to ICIs were observed in patients with truncating mutations in JAK-1 or JAK-2 that 
inhibited the function of IFN-γ signalling in tumours (122, 126). Low PD-L1 expression, 
downregulation of antigen presentation, the lack of anti-proliferative effect of IFN-γ, and 
inhibition of tumour infiltration by T cells might have caused the resistance to ICIs in 
tumours insensitive to IFN-γ (122, 126, 127). Expression of immunosuppressive 
molecules by tumour cells may bypass blockade of PD-1/PD-L1 and mediate resistance 
to ICIs (128–130). For example, IDO, prostaglandin E2, IL-10, or transforming growth 
factor β (TGF-β) may promote differentiation of immune cells into immunosuppressive 
phenotype, which enhance tumour growth, such as Treg cells, M2 macrophages, or 
MDSCs. PD-1/PD-L1 blockade may be compensated by upregulation of additional 
immune checkpoints, such as CTLA-4, Tim-3, TIGIT, or Lag-3 (11, 131). Another study 
reported that CTLA-4, Tim-3, Lag-3, or BTLA blockade synergised with inhibition of 
PD-1/PD-L1 axis (132). Thus, single ICI may be less effective than simultaneous 
targeting of different pathways in cancer treatment. A single blockade of PD-1/PD-L1 
axis may strengthen CTLA-4/CD80 signalling, as PD-L1 interaction with CD80 in cis 




Resistance to PD-1/PD-L1 blockade may also be mediated by PD-L1 on the surface of 
exosomes, which inhibits the effector functions of CD8+ T cells and induce apoptosis of 
these cells (134, 135). However, the mechanism of exosomal PD-L1 mediated resistance 
to the anti-PD-L1 is unclear. 
Furthermore, extrinsic factors, such as gut microbiota, may influence immune 
reactions and sensitivity to ICIs (136). The impact of gut microbiota on the sensitivity to 
ICIs was tested  in germ-free mice that received faecal transplantation from cancer 
patients (137–139). The efficacy of ICIs observed in cancer patients was preserved in 
mice, in that study. Moreover, it was determined that changed microbiota composition 
after treatment with antibiotics, tyrosine kinase inhibitors (TKIs), or corticosteroids may 
induce primary resistance to ICIs (137, 140). For example, deficiency of Akkermansia 
muciniphila (Verrucomicrobiae order) in the gut of the NSCLC, and RCC patients and 
Bacteroides salyersiae (Bacteroidales order) in the RCC patients correlated with 
resistance to blockade of PD-1/PD-L1 axis (137, 139). Moreover, Bacteroidales order 
was abundant in non-responders to anti-PD-1 in metastatic melanoma patients (141).  
Besides resistance to ICIs, some individuals may develop hyper-progressive 
disease, a rapid increase of tumour growth after treatment with ICIs which is significantly 
faster than in non-responders (142). The hyper-progressive disease may be mediated by 
rapid proliferation and immunosuppressive functions of Treg cells, exhausted T cells, M2 
macrophages, or MDSCs (143). However, mechanisms inducing the hyper-progressive 
disease are not completely understood. 
1.5. Predictive markers of response to immune checkpoint inhibitors  
1.5.1. The tumour microenvironment  
The tumour microenvironment regulates the therapeutic outcome of ICIs. 
Accordingly, the characteristics of tumour microenvironment may predict efficacy of the 
therapy (144). Analysis of PD-L1 expression on tumour cells or tumour infiltrating cells 
was approved as the first predictive biomarker for response to PD-1/PD-L1 blockade in 
several tumour types (Fig. 2). However, PD-L1 expression as a single biomarker was 
predictive in only 28.9% of various cancer cases (145). Low sensitivity of 
immunohistochemistry (IHC), a standard technique of PD-L1 detection in the tumour 




Therefore, more sensitive methodologies are being developed, such as radiolabelled 
monoclonal antibodies imaging with positron-emission tomography (PET) (146). PD-L1 
imaging with PET predicted the response of cancer patients to blockade of PD-1/PD-L1 
more accurately than IHC. Standardisation of diagnostic assays in clinical use and 
biomarkers additional to PD-L1 expression in tumours should increase accuracy to 
predict the sensitivity of patients to ICIs (147). Thus, predictive value of various markers 
is investigated.  
The level of immune cell infiltration into tumour and a functional state of tumour 
infiltrating cells are fundamental factors in the therapeutic outcome of ICIs. The 
frequency of selected immune cells infiltrating tumours was described as an 
Figure 2: PD-L1 testing as a companion diagnostic for administration of immune 
checkpoint inhibitors. Bars represents the number of FDA approvals for immune 
checkpoint inhibitors (pembrolizumab (N = 18), nivolumab (N = 11), atezolizumab (N 
= 5), ipilimumab with nivolumab (N = 3), ipilimumab (N = 2), durvalumab (N = 2), 
cemiplimab (N = 2), and avelumab (N = 2). The dark-gray colour illustrates approved 
and the light-grey colour non-approved PD-L1 testing. Abbreviations: gastro-
oesophageal junction (GEJ), hepatocellular carcinoma (HCC), Hodgkin’s Lymphoma 
(HL), non-small-cell lung cancer (NSCLC), primary mediastinal B-cell lymphoma 
(PMBCL), renal cell carcinoma (RCC), squamous cell carcinoma (SCC), small-cell lung 




„immunoscore” (148). As CD8+ T cells play the major role in tumour rejection in 
response to ICIs, the accumulation of these cells in tumours is evaluated together with 
expression of PD-1 and PD-L1 (149). Enhanced abundance of CD8+, PD-1+, or PD-L1+ 
cells in tumours, detected by IHC before treatment with ICIs, predicted the response in 
melanoma patients (11, 150). These studies showed that blockade of PD-1/PD-L1 axis 
induced CD8+ T cell proliferation, activation of effector functions, infiltration into tumour 
parenchyma, and control of tumour growth. On the contrary to these studies, the 
frequency of CD8+ T cells and the ratio of CD4+/CD8+ cells was not associated with 
response to ICIs in metastatic melanoma patients receiving ipilimumab, pembrolizumab 
or nivolumab, although the level of tumour infiltration by lymphocytes correlated with 
OS (148). Furthermore, expression of immune checkpoints on CD8+ T cells infiltrated 
into tumour has been reported as a predictive marker for ICIs in cancer (151). In that 
study, partially exhausted (PD-1+ CTLA-4+) CD8+ T cells infiltrated into tumour 
predicted response to pembrolizumab or nivolumab in metastatic melanoma patients. The 
study indicated that the frequency of partially exhausted CD8+ T cells exceeding 20% of 
all tumour infiltrating CD8+ T cells detected before treatment was associated with 
significantly higher response rate (RR) and longer progression free survival (PFS) after 
PD-1 blockade. The treatment induced functional activation of CD8+ T cells and 
infiltration into tumours, while infiltration of CD4+ T cells declined and the ratio of 
CD4+/CD8+ cells was decreased. Accumulation of tumour-antigen-specific exhausted 
CD8+ T cells within the tumours, especially tissue-resident memory cells (CD103+ CD69+ 
CD49a+), was also a predictive factor of response to PD-1/PD-L1 blockade in patients 
with HNSCC (152). ICIs restored effector functions of exhausted cells, induced 
proliferation of memory T cells in the circulation, and initiated anti-tumour immune 
response. Moreover, effector memory (EOMES+ CD69+ CD45RO+) T cells were 
associated with prolonged PFS in melanoma patients, and upregulated abundance of these 
cells was predictive of response to ICIs (11).  
Besides T cell infiltration into tumours and immune checkpoint expression by 
these cells, diversity of TCR repertoire and clonal expansion was evaluated as a predictive 
marker of response to ICIs. Accumulation of T cells in tumours correlated with reduced 
diversity of TCR β-chain and upregulated clonality in melanoma patients subsequently 
responding to pembrolizumab (150). Proliferation was restricted to tumour-specific T 




Another study evaluated the predictive value of TCR diversity and clonality in peripheral 
blood T cells (153). The high clonality and the lack of TCR diversity predicted a 
favourable outcome of pembrolizumab, or nivolumab, but poor response to anti-CTLA-
4 in melanoma patients. 
1.5.2. Genetic alterations in tumours 
 Genetic instability enhances tumour immunogenicity and sensitivity to 
immunotherapy. The predictive capacity of tumour mutational burden (TMB) in the 
immune checkpoint blockade has been evaluated in cancer patients. The level of TMB 
predicted therapeutic outcome in a dataset of patients with various tumour types 
(melanoma, NSCLC, and 19 other types of tumours; N = 52, 36, and 63 patients, 
respectively) (154). In that study, the RR after PD-1/PD-L1 blockade was approx. three 
times higher in patients with high TMB than in patients with low to intermediate TMB 
across all tumour types. Interestingly, TMB was not predictive of the combined PD-1/PD-
L1 and CTLA-4 blockade. Other studies evaluated TMB as a predictive marker for 
specific types of cancer, such as melanoma, NSCLC, or metastatic RCC (77, 155–157). 
TMB correlated with the probability of response to PD-1 blockade in melanoma (77). 
Furthermore, nivolumab and ipilimumab were significantly more efficient than 
chemotherapy in stage IV or recurrent NSCLC patients with high TMB compared with 
low TMB tumours (155). However, TMB was not predictive in metastatic RCC patients 
treated with nivolumab and/or ipilimumab or pembrolizumab (156). Despite the 
correlation of TMB with response to ICIs in several studies, 54.5% of patients with high 
TMB in various tumour types did not respond to PD-1/PD-L1 blockade (158). Therefore, 
the combination of TMB with additional markers may improve prediction accuracy in 
cancer.  
Besides TMB, mismatch repair (MMR) and microsatellite instability (MSI) have 
been evaluated as predictive markers of response to ICIs (159). The frequency of defects 
in deoxyribonucleic acid (DNA) repair, including MMR, did not correlate with RR to PD-
1/PD-L1 blockade across 13 different cancer types (112). Moreover, proficient MMR, 
low status of MSI, and low to intermediate TMB were identified in a fraction of cancer 
patients who achieved objective response to ICIs (154, 160). In contrast to those studies, 




suitable for the therapy with ICIs (161). In that study, MSI had stronger predictive 
capacity than PD-L1 expression.  
Determination of the immunoscore alongside the MMR and MSI may improve 
the accuracy of prediction which patients may benefit from ICIs. In most cases, deficiency 
of MMR and high MSI correlated with upregulated expression of PD-L1 and PD-L2, 
infiltration of CD4+ and CD8+ cells and enhanced activation of IFN-γ signalling in 
majority of patients with colorectal cancer (CRC) (160). However, the study also showed 
increased PD-L1 expression and activated IFN-γ signalling in tumours with proficient 
MMR and low MSI. In that tumours, the level of CD4+ and CD8+ cells infiltration was 
comparable to high MSI tumours and therefore PD-1/PD-L1 blockade may be efficient 
in both tumour types.  
Genetic instability may generate immunogenic neoantigens (154, 162). Therefore, 
the occurrence of neoantigens is evaluated alongside markers of genetic instability in 
order to predict the efficacy of ICIs. For example, increased somatic non-synonymous 
TMB and neoantigens detected in NSCLC correlated with favourable prognosis  in 
response to pembrolizumab (upregulated (ORR), durable clinical benefit (DCB), and 
PFS) (163). Another study was conducted on 12 different types of advanced cancer 
deficient in MMR and with  high MSI status (113). In that study, expansion of neoantigen 
specific T cells was identified in responders to pembrolizumab, according to the 
sequencing analysis of CDR3 regions of TCR. Moreover, neoantigens suitable for 
presentation on MHC molecules have been shown to correlate with better clinical 
outcome of patients with high TMB in different types of solid tumours treated with ICIs 
(158). Genotype of HLA corresponds to the repertoire of epitopes presented on MHC 
molecules (164). Patients with heterozygosity at HLA-I, and especially HLA-B44 allele, 
had a significantly better outcome of ICIs compared to patients with loss of 
heterozygosity or HLA-B62.  
 Furthermore, copy number chromosomal aberrations in various types of cancer 
are associated with the efficacy of ICIs. Focal copy number gain of 9p24.1, which 
upregulates PD-L1, PD-L2, and JAK-2 expression, occurred in several malignancies, 
such as Hodgkin’s lymphoma (HL), triple-negative breast cancer (TNB), diffuse large B 
cell lymphoma, hepatocellular carcinoma (HCC) or CRC (69, 166–169).  Predictive value 




efficacy of ICIs. PD-L1 was amplified in 0.7% of various types of solid tumours and 
66.7% of patients with the upregulation of this gene responded to ICIs independently of 
TMB or MSI (52). Furthermore, nivolumab was an effective treatment in relapsed or 
refractory HL and the majority of patients bearing this type of tumour responded to the 
therapy (166, 170). All patients in the study had genetic alterations of the PD-L1 and PD-
L2 loci, and upregulation of PD-L1 protein production was associated with increased 
efficacy of nivolumab (170). Upregulated PD-L1 was also detected in patients with rare 
types of large B-cell lymphoma (relapsed/refractory primary central nervous system and 
testicular lymphoma) sensitive to nivolumab (171). The portion of responders to 
pembrolizumab in relapsed or refractory classical HL was similar to nivolumab and the 
majority of tumours were PD-L1+, presumably due to 9p24.1 genetic alteration (172). 
Moreover, enhanced efficacy of pembrolizumab in a patient with advanced CRC and 
9p24.1 copy number gain in liver metastasis further supports the predictive value of this 
biomarker (168). 
1.5.3. Viruses and microbiota 
Some viruses associated with tumorigenesis may affect sensitivity to ICIs and 
serve as predictive markers. For instance, detection of  EBV strongly correlated with 
enhanced ORR to pembrolizumab in mGC (161). On the contrary, Merkel cell 
polyomavirus (MCPyV) detected in patients did not correlate with the response to 
pembrolizumab in Merkel cell carcinoma (MCC) (34). Instead of the MCPyV status, the 
high abundance of PD-1+ and PD-L1+ cells in tumours and the interaction of these 
molecules were associated with clinical outcome. Another study also reported that 
MCPyV did not correlate with response to pembrolizumab in MCC (173). Furthermore, 
sensitivity to nivolumab was independent of HPV infection or PD-L1 expression in 
patients with HNSCC (174).  
Treatment with antibiotics prior to administration of ICIs predicted reduced OS 
and PFS of cancer patients due to altered composition of microbiota (175). Several studies 
analysed the enrichment of particular bacterial species in the gut of melanoma patients 
before treatment and its impact on the efficacy of ICIs (138, 141, 176). For instance, 
Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium indicated 
response to the PD-1 blockade (138). Moreover, Faecalibacterium in melanoma patients 




order and Ruminococcaceae family were enriched in the gut of responders to anti-PD-1 
in metastatic melanoma patients (141). As the level of tumour infiltrating leucocytes is 
associated with the efficacy of ICIs, the impact of bacteria on immune cell infiltration 
into tumours has been assessed in some studies (139, 141). For instance, A. muciniphila 
increased the accumulation of CD4+ T cells in mouse tumours (139). Moreover, the 
occurrence of other bacteria, Faecalibacterium genus (Clostridiales order), in the gut of 
melanoma patients correlated with increased abundance of CD4+ and CD8+ T cells in the 
periphery and it enhanced the accumulation of CD8+ T cells in the tumours (141). On the 
contrary, the high abundance of Bacteroidales supported the increased frequency of Treg 
cells and MDSCs in the circulation and promoted resistance to PD-1 blockade in that 
study. 
1.5.4. Systemic factors  
Liquid biopsy is advantageous in routine clinical practice thanks to its feasibility 
and non-invasiveness. Prognostic value of several systemic factors examined from the 
blood of cancer patients is studied in order to monitor the efficacy of ICIs and to predict 
the suitability of treatment. Circulating tumour cells (CTC) and expression of 
immunosuppressive molecules by CTC appeared to be prognostic in patients receiving 
PD-1/PD-L1 inhibitors (177–179). CTC in the peripheral blood and PD-L1 expression on 
these cells during the therapy correlated with inferior outcome of NSCLC and urothelial 
cancer (UC) patients (177, 178, 180). Expression of IDO in CTC indicated shorter PFS 
and OS, and increased risk of death in advanced NSCLC patients treated with anti-PD-1, 
while PD-L1 surface expression on CTC was not predictive (179). Moreover, the amount 
of circulating tumour DNA was associated with response to CTLA-4 and PD-1/PD-L1 
blockade in various types of tumours (161, 181, 182).  
The composition of immune cells in the peripheral blood was evaluated as a 
predictive marker of sensitivity to ICIs. The frequency of CD14+CD16-HLA-DRhi 
monocytes was described as a strong predictive marker of response to pembrolizumab or 
nivolumab in patients with stage IV melanoma (183). In that study, high frequency of 
monocytes and low frequency of T cells in the blood of responders indicated T cell 
accumulation in tumours before treatment. The frequency of activated T cells, central 
memory T cells, and NKT cells was enhanced in the circulation after PD-1 blockade in 




peripheral blood in patients with NSCLC receiving pembrolizumab or nivolumab (184). 
Cytokines (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12) detected 
before therapy did not predict therapeutic outcome of ICIs. However, increased 
concentration of these cytokines after treatment markedly correlated with favourable 
prognosis. Another study showed that increased concentration of IFN-γ in blood samples, 
which were stimulated with tuberculosis antigen in vitro, predicted response to PD-1/PD-
L1 blockade in NSCLC patients treated with nivolumab, pembrolizumab, or atezolizumab 
(185). 
1.5.5. IFN-γ signalling  
  Several studies tested the capacity of IFN-γ and IFN-γ-related genes to predict the 
therapeutic outcome of ICIs in various cancer types (11, 124, 186). Expression of IFN-γ 
and IFN-γ-related genes correlated with “hot”/”inflamed” tumour microenvironment and 
predicted response to ICIs in cancer patients (186, 187). For instance, the expression of 
IFN-γ and IFN-γ-inducible genes were upregulated in melanoma before atezolizumab 
administration in responders (187). Furthermore, the set of IFN-γ-responsive genes, 
which represented activation of IFN-γ signalling, activation and effector functions of 
immune cells and recruitment of CD8+ T cells into tumours, predicted the efficacy of 
pembrolizumab (186). The set of IFN-γ-responsive genes was initially defined in 
melanoma and HNSCC patients and subsequently validated on a large cohort of patients 
with nine different cancer types. Moreover, IFNG expression and markers of IFN-γ 
stimulation in tumours before treatment were predictive in melanoma patients responding 
to nivolumab (124). Another study determined the expression of genes associated with 
IFN-γ and its downstream signalling, such as STAT1 and IRF1 (11). Expression of these 
genes correlated with response to nivolumab or pembrolizumab in melanoma patients. 
Similarly, elevation of pSTAT1 and its spatial colocalization with CD8+  cells at the 
invasive tumour margin indicated the response to pembrolizumab in metastatic melanoma 
(150). Moreover, IFN-γ expression signature in tumour microenvironment predicted the 
efficacy of ICIs in NSCLC patients (77). In that study, the response to anti-PD-1 and anti-
CTLA-4 therapy surprisingly correlated with mutations in IFN type I and II pathways, on 
the contrary to the aforementioned studies. This observation further supports the dual role 




1.6.  Integration of immune checkpoint blockade predictive markers 
 High throughput techniques have been used to integrate various predictive 
markers to ICIs based on genomic and transcriptomic features (188, 189). TMB did not 
predict sensitivity to ICIs in melanoma in these studies. However, mutations in the DNA 
repair gene BRCA2 were identified in tumours of responders, while innate anti-PD-1 
resistance signature (IPRES) characterised by upregulated transcription of genes 
associated with angiogenesis, hypoxia, remodelling of extracellular matrix, and 
mesenchymal transition predicted primary resistance to the treatment (188). Model 
integrating clinical, genomic and transcriptomic characteristics of tumours showed that 
MHC-II expression, tumour purity (the proportion of tumour cells in the tumour tissue), 
heterogeneity (the occurrence of subclonal mutations), and ploidy predicted response to 
anti-PD-1 (189). Next, markers of resistance to PD-1/PD-L1 blockade were determined 
in the tumour microenvironment based on clinical-grade RNA sequencing assay (190). 
Expression of immune checkpoint molecules Tim3 and VISTA, and CD68 marker of 
macrophages predicted worst clinical outcome and markedly shorter PFS in patients with 
diverse types of tumours treated with PD-1/PD-L1 blockade. 
In conclusion, cancer is a heterogeneous disease and multiple factors affect the 
therapeutic outcome of ICIs. Besides the integration of biomarkers, a personalized 
approach would improve the accuracy of patient selection for the therapy. A tool “cancer 
immunogram” designed to evaluate the probability of response to ICIs based on multiple 
parameters  has been recently introduced (191). The cancer immunogram comprises 
markers that represent the level of immune cell infiltration, mutational status, occurrence 
of neoantigens, and the degree of immunosuppression in tumours. Subsequent studies 
introduced alternative cancer immunograms related to UC or NSCLC (192, 193). 
Development of immunograms related to additional cancer types and extension of a set 





During my doctoral studies, I focused on the development of clinically relevant 
experimental mouse tumour models with altered expression of molecules involved in 
anti-tumour immune response and regulation of sensitivity to cancer immunotherapy.  
The main aims of the dissertation thesis were: 
 To assess whether deactivation of IFN-γ signalling in tumour cells with reversibly 
downregulated PD-L1 and MHC-I may be a contraindication to PD-1/PD-L1 
blockade and to evaluate the impact of cytokines on PD-L1 and/or MHC-I 
expression on tumour cells. 
 To characterise the microenvironment of tumours with deactivation of CD80 
costimulatory molecules and to test the sensitivity of these tumours to the ICIs. 
Besides the main projects of this thesis, I participated in two projects focused on 
mouse tumour models characterized by downregulation of MHC-I molecules. The aim of 
the first project was to test experimental combined immunotherapy against tumours with 
reversible MHC-I downregulation. In the second project, the aim was to generate a mouse 
tumour model with irreversible downregulation of MHC-I molecules and to examine the 





3. RESULTS AND DISCUSSION 
3.1. Publication 1: Abrogation of IFN-γ signalling may not worsen 
sensitivity to PD-1/PD-L1 blockade 
3.1.1. Main characteristics of cell lines used in the study 
In order to assess whether the IFN-γ signalling regulates the efficacy of the PD-
1/PD-L1 blockade, we used mouse oncogenic TC-1 cell line, which was prepared by 
transformation of primary C57BL/6 mouse lung cells with the HPV16 E6/E7 oncogenes 
and human activated H-ras. This cell line was kindly provided by Dr. T.-C. Wu, John 
Hopkins University, Baltimore, MD, USA (194). These cells constitutively express PD-
L1 and MHC-I. Next, TC-1/A9 cell line with reversible downregulation of PD-L1 and 
MHC-I was generated from the TC-1 cell line (195). The expression of both molecules 
can be induced by cytokines, such as IFN-γ. We used TC-1 and TC-1/A9 cell lines to 
generate cells insensitive to IFN-γ (TC-1/dIfngr1 and TC-1/A9/dIfngr1). We functionally 
deactivated the IFNGR1 subunit of the IFN-γ receptor with the CRISPR/Cas9 system 
(Publication 1, Fig. 1A). Oncogenicity of the TC-1/dIfngr1 or TC-1/A9/dIfngr1 cells was 
comparable to that of the TC-1 or TC-1/A9 cells, respectively (Publication 1 Fig. 1B). 
This finding is in line with a previous study that has also shown similar oncogenicity of 
melanoma cells with deactivated expression of IFNGR1 and parental cells (196).   
As the enhancement of tumour growth by PD-L1, expressed on tumour cells and 
host cells, is dependent on tumour type (47–51), we evaluated the role of PD-L1 in the 
oncogenicity of TC-1 and TC-1/A9 cell lines. We deactivated PD-L1 molecule with the 
CRISPR/Cas9 system and produced TC-1/dPD-L1 and TC-1/A9/dPD-L1 cells 
(Publication 1, Fig. 1C). Mice injected with various doses (3 x 104, 3 x 105, and 3 x 106) 
of TC-1/dPD-L1 cells did not form any tumour and only the 1 x 105 dose induced tumour 
formation in two out of five mice (Publication 1, Fig. 1D). The TC-1/A9/dPD-L1 cells 
were more oncogenic than the TC-1/dPD-L1 cells. However, the growth of TC-
1/A9/dPD-L1-induced tumours was significantly slower in comparison with TC-1/A9-
induced tumours. The reduced oncogenicity of both cell lines suggests the involvement 
of PD-L1 expression on tumour cells in the suppression of anti-tumour immunity and 





3.1.2. The role of IFNGR1 in anti-tumour immunity 
We next tested the impact of IFNGR1 deactivation in tumour cells on pro-/anti-
oncogenic function of CD4+, CD8+, NK1.1+ and macrophages in mouse tumours 
(Publication 1, Fig. 2). We depleted immune cells in tumour bearing mice with anti-CD4, 
anti-CD8, or anti-NK1.1 antibody and treated mice with carrageenan to achieve 
macrophage depletion. As IFN-γ signalling of host cells was functional in tumours with 
IFNGR1 deactivation, we also treated mice with anti-IFN-γ in order to evaluate the effect 
of IFN-γ on tumour growth. Deactivation of IFNGR1 in TC-1 cells eliminated the anti-
oncogenic role of CD8+ cells and pro-oncogenic role of macrophages, while anti-
oncogenic function of NK1.1+ cells and IFN-γ remained preserved in TC-1/dIfngr1-
induced tumours. Only NK1.1+ cells were anti-oncogenic in TC-1/A9-induced tumours, 
which was not preserved in TC-1/A9/dIfngr1-induced tumours. Interestingly, 
deactivation of IFNGR1 in TC-1/A9 promoted the pro-oncogenic function of IFN-γ. The 
mechanisms of the impact of IFNGR1 deactivation in tumour cells on alterations in pro-
/anti-oncogenic immune cell functions are currently unclear. 
3.1.3. PD-L1 and MHC-I expression in tumours in comparison with cell lines 
Furthermore, we analysed PD-L1 and MHC-I expression on tumour cells obtained 
from tumours (Publication 1, Fig. 3).  The expression of both molecules was slightly 
upregulated on TC-1/dIfngr1 and TC-1/A9/dIfngr1 cells isolated from tumours compared 
with parental cells. Moreover, the expression on TC-1/A9/dIfngr1 cells in tumours was 
comparable to the level of expression on TC-1/A9 cells stimulated with IFN-γ in vitro. 
These data suggest that besides IFN-γ, other factors induced PD-L1 and MHC-I 
expression on tumour cells in the tumour microenvironment. 
3.1.4. Detection of cytokines in tumours and their secretion by cell lines 
Multiple factors may induce PD-L1 or MHC-I expression, such as IFN-γ, IFN-α, 
IFN-β, IL-1α, IL-6, IL-27, TNF-α, chemokine CCL2, GM-CSF, and EGF (80, 86, 88–95, 
97, 98). We therefore analysed the occurrence of these presumed inducers of PD-L1 
and/or MHC-I expression in tumours and cell lines with a LEGENDplex assay 
(Publication 1, Fig. 4A). We found almost all cytokines in tumours. The exception was 
the absence of IFN-α in TC-1- and TC-1/dIfngr1-induced tumours. The cell lines 
produced IL-6 and CCL2. Downregulation of PD-L1 and MHC-I expression on TC-1/A9 




therefore excluded these two cytokines from further analysis and tested the effect of 
remaining cytokines on PD-L1 and MHC-I expression in vitro (Publication 1, Fig. 4B). 
Among these cytokines, IFN-α and IFN-β significantly increased PD-L1 and MHC-I, 
especially on TC-1/A9 and TC-1/A9/dIfngr1 cells. Relative upregulation of both 
molecules on TC-1/A9/dIfngr1 cells by type I IFNs was comparable to the effect of IFN-
γ on TC-1/A9 cells. TNF-α slightly induced MHC-I expression on TC-1/A9/dIfngr1 cells. 
According to previous studies, type I IFNs promote anti-tumour immune response and 
may enhance the efficacy of ICIs (197, 198). Our data indicate that type I IFNs can be 
potent inducers of PD-L1 and MHC-I expression on tumour cells that are insensitive to 
IFN-γ signalling.  
3.1.5. PD-L1 and MHC-I expression in tumours with blockade of IFN-α and 
IFN-β signalling  
We next assessed the effect of type I IFNs on PD-L1 and MHC-I expression in 
mouse tumours (Publication 1, Fig. 5). We neutralized IFN-α and IFN-β function by 
antagonistic monoclonal antibody anti-IFNAR1, which targets a shared IFN-α and IFN-
β receptor, in mice bearing TC-1/dIfngr1- and TC-1/A9/dIfngr1-induced tumours. The 
PD-L1 and MHC-I expression was markedly downregulated on TC-1/A9/dIfngr1 tumour 
cells isolated from mice treated with anti-IFNAR1, whereas the expression on TC-
1/dIfngr1 was not significantly changed. As mentioned above, IFN-α was not detected in 
TC-1/dIfngr1-induced tumours, whereas this cytokine was present in TC-1/A9/dIfngr1-
induced tumours. The expression of PD-L1 and MHC-I on TC-1/A9/dIfngr1 cells isolated 
from tumours was comparable to the expression of IFN-γ stimulated TC-1/A9 cells in 
vitro. It implies the predominant contribution of IFN-α in PD-L1 and MHC-I stimulation 
on tumour cells in vivo, although the concentration of IFN-β was higher than the 
concentration of IFN-α in all tumours. Type I IFNs are important inducers of anti-tumour 
immune response and IFN-α has been particularly shown to enhance the efficacy of PD-
L1 blockade (197, 198). In line with the previous studies, we hypothesised that type I 
IFNs might have enhanced the efficacy of PD-1/PD-L1 blockade in TC-1/A9/dIfngr1-
induced tumours. 
3.1.6. Sensitivity of tumours to combined therapy 
Finally, we evaluated the sensitivity of TC-1/A9- and TC-1/A9/dIfngr1-induced 




with DNA vaccination in order to stimulate the immune response against HPV16 E7 
oncoprotein. TC-1/A9- as well as TC-1/A9/dIfngr1-induced tumours were sensitive to 
PD-L1 blockade in combination with the DNA vaccination. Sensitivity to immune 
checkpoint inhibition in tumours with deactivated IFN-γ signalling has been also studied 
in mouse tumours induced by CRC cell line (CT26) (77). Unlike the TC-1/A9 cell line 
with cytokine inducible MHC-I expression used in our study, the CT26 cells are highly 
immunogenic due to the constitutive expression of MHC-I. Deactivation of IFNGR and 
IFNAR promoted the efficacy of PD-1/PD-L1 blockade owing to the inhibition of 
resistance-associated IFN stimulated genes in CT26-induced tumours.  
Recent evidence suggests that mutations in Ifngr1, Ifngr2, JAK1, and JAK2, 
involved in IFN-γ signalling, were detected in cancer patients regardless of response to 
PD-1/PD-L1 blockade (123, 157, 188, 199–201). These studies further support the 
clinical relevance of our model of PD-1/PD-L1 blockade in mice bearing tumours with 
deactivated IFN-γ signalling. Therefore, reduced sensitivity of tumour cells to IFN-γ as a 
single predictive marker should not be a contraindication to PD-1/PD-L1 blockade. In 
conclusion, the predictive capacity of both, IFN-γ and type I IFNs signalling should be 
evaluated in PD-1/PD-L1 blockade. 
3.2. Publication 2: CD80 expression on tumour cells alters tumour 
microenvironment and the efficacy of cancer immunotherapy by 
CTLA-4 blockade  
CD80 is expressed by tumour cells as well as host cells and its pro-/anti-oncogenic 
nature depends on various factors (202–206). In this study, we aimed to determine 
whether CD80 expressed by tumour cells affects the tumour microenvironment and 
sensitivity to ICIs. 
3.2.1. Characteristics of TC-1/dCD80-1 cancer cell line 
Firstly, we deactivated CD80 molecule in the TC-1 oncogenic cell line with 
CRISPR/Cas9 system and generated TC-1/dCD80-1 cells (Publication 2, Fig. 1). These 
cells were more immunogenic than TC-1 cell line (Publication 2, Fig. 2A). Ten times 
higher dose of TC-1/dCD80-1 than TC-1 cells formed tumours of comparable growth 
(Publication 2, Fig. 2B). Our observation is in agreement with previously reported 




3.2.2. CD80 expression on tumour cells regulates immune reactions 
Next, we analysed whether CD80 on tumour cells regulate anti-tumour immune 
response (Publication 2, Fig. 3). The deactivation of CD80 switched pro-oncogenic nature 
of macrophages to anti-oncogenic and abrogated the anti-oncogenic function of NK1.1+ 
cells. Consistent with our findings, another study has shown that CD80 expression on 
tumour cells enhanced NK cell-mediated control of tumour growth (207). Furthermore, 
CD80 deactivation promoted the immunosuppressive activity of CD4+ cells, while the 
anti-oncogenic function of CD8+ cells remained preserved in the TC-1/dCD80-1-induced 
tumours in our study. CD4+ T cells express CTLA-4 with higher intensity than CD8+ T 
cells (20). As CD80 is still expressed by host cells in mice bearing TC-1/dCD80-1-
induced tumours, enhancement of CTLA-4 expression by CD4+ cells might contribute to 
immunosuppressive mechanisms.  
3.2.3. CD80 expression on tumour cells affects sensitivity to CTLA-4 blockade 
We next tested the effect of CTLA-4 blockade in TC-1- and TC-1/dCD80-1-
induced tumours (Publication 2, Fig. 4). CD80 deactivation induced sensitivity of 
tumours to CTLA-4 blockade. However, PD-L1 blockade did not significantly reduce 
tumour growth and it did not support the effect of CTLA-4 blockade regardless of CD80 
expression on tumour cells. Depletion of immune cells in mice bearing TC-1/dCD80-1-
induced tumours showed that CD8+ cells were essential for the efficacy of anti-CTLA-4 
treatment, whereas depletion of CD4+ cells supported the effect of the therapy. Similarly, 
direct killing of tumour cells by activated CD8+ T cells in anti-CTLA-4 treated tumours 
has been previously reported (208, 209). 
3.2.4. CD80 expression on tumour cells regulates tumour microenvironment 
We designed flow cytometry panels to compare microenvironment of TC-1- and 
TC-1/dCD80-1-induced tumours. CD80 deactivation enhanced the frequency of both 
lymphoid and myeloid cells in tumours (Publication 2, Fig. 5). Another studies have 
shown that CD80 blockade induced infiltration of mouse adenocarcinoma (210, 211). 
Furthermore, the frequency of M1 macrophages increased and M2 decreased in the TC-
1/dCD80-1- compared with the TC-1-induced tumours. Our data are in line with a 
previous study which has shown that blockade of CTLA-4/CD80 axis induced M1 
polarization of macrophages in melanoma patients (212). Moreover, CD80 deactivation 




APCs in tumours. Consistently, enhanced APCs co-stimulation of lymphocytes has been 
reported to induce CTLA-4 expression, particularly on Th17 cells (213). 
Moreover, the CTLA-4 blockade downregulated frequencies of most immune cell 
types in the TC-1-induced tumours, whereas it promoted the frequency of lymphoid cells 
in the TC-1/dCD80-1-induced tumours (Publication 2, Fig. 6). Within the CD4+ T cells, 
especially the frequency of Th1 subset was enhanced in TC-1/CD80-1-, unlike the TC-1-
induced tumours. Increased infiltration of tumours by Th1 cells has been previously 
shown in mouse models as well as cancer patients treated with CTLA-4 blockade (196, 
214, 215).  
3.2.5. CD80 expression regulates immunosuppressive potential of Treg cells 
The Treg cells were the most abundant CD4+ T cell subset in untreated tumours. 
In order to analyse immunosuppressive potential of Treg cells, we measured expression 
of markers CTLA-4, GITR, ICOS, Lag3, CD73, granzyme B (GrzB), and neuropilin 1 
(Nrp-1), which imply immunosuppressive potential of Treg cells (216–220), (Publication 
2, Fig. 7). Furthermore, we performed unsupervised clustering by FlowSOM algorithm 
and generated four distinct Treg subpopulations (subpopulation 1 (CTLA-4hi GITRhi 
ICOShi Lag3lo CD73- GrzB+ Nrp-1lo) and subpopulation 2 (CTLA-4hi GITRhi ICOShi 
Lag3lo CD73+ GrzB+ Nrp-1lo) with high immunosuppressive potential, and subpopulation 
3 (CTLA-4- GITRhi ICOShi Lag3+ CD73+ GrzB+ Nrp-1lo) and subpopulation 4 (CTLA-4lo 
GITRlo ICOSlo Lag3- CD73+ GrzB+ Nrp-1+) with weak immunosuppressive potential). 
The anti-CTLA-4 treatment downregulated the frequency of subpopulation 3 Treg cells 
in the TC-1-induced tumours, while it supported these cells and reduced frequency of 
subpopulation 2 Treg cells in the TC-1/dCD80-1-induced tumours.  
Collectively, our data indicate that CD80 deactivation in tumour cells promotes 
infiltration of immune cells into tumours, inhibits the immunosuppressive 
microenvironment and enhances tumour sensitivity to CTLA-4 blockade. 
3.3. Publication 3: Experimental combined immunotherapy of tumours 
with major histocompatibility complex class I downregulation 
We have previously shown that the immune response to DNA vaccination 
targeting tumour specific antigen E7 in TC-1/A9-induced tumours was weak in 




DNA vaccination by combination with adjuvants in mice bearing tumours induced by 
parental TC-1 cells (221). Several other studies have also reported that combined cancer 
therapy targeting innate as well as adaptive immunity is more efficient than a single 
therapy (222, 223). To achieve the immune response against the TC-1/A9-induced 
tumours, we tested combined therapy comprising DNA vaccination against the tumour 
specific antigen E7, an adjuvant (oligodeoxynucleotide (ODN) 1585, levamisole, ODN 
1826, or α-galactosylceramide (α-GalCer) – the mechanisms of action of these 
compounds have been reviewed in the study (224), and the immune checkpoint blockade 
with anti-Tim-3 monoclonal antibody (Publication 3, Fig. 1). The adjuvants alone did not 
significantly influence tumour growth. Administration of ODN 1826 or α-GalCer 
combined with DNA vaccination markedly reduced tumour growth and some tumours 
completely regressed. This observation indicates indispensable cooperation of the innate 
immune system and tumour specific adaptive immunity in tumour regression. Moreover, 
anti-Tim-3 antibody enhanced the reduction of tumour growth in mice treated with 
combination of ODN 1826, α-GalCer and DNA vaccine. Next, we delayed the 
administration of adjuvants by one week after DNA vaccination and achieved enhanced 
efficacy of the therapy (Publication 3, Fig. 2). Tim-3 blockade unfortunately did not have 
a significant additional effect in the modified schedule. 
Furthermore, we performed flow cytometry analysis of tumours during the period 
of tumour regression induced by combined therapy (Publication 3, Fig. 3). Administration 
of adjuvants in combination with DNA vaccine increased the frequency of CD45+ 
immune cells in tumours (Publication 3, Fig. 3A), particularly CD8+ T cells, cDCs, and 
neutrophils (Publication 3, Fig. 3B). Tim-3 blockade did not have additional effect to the 
combined therapy. Moreover, the frequency of Treg cells in CD3+ population was 
reduced (Publication 3, Fig. 3A). We also analysed the frequency of Nrp-1+ Treg cells, 
because Nrp-1 stabilise the phenotype of Treg cells and promote the survival and 
immunosuppressive function of these cells in the tumour microenvironment (225). 
Treatment of mice with adjuvants or anti-Tim-3 monoclonal antibody combined with 
DNA vaccination reduced the frequency of Nrp1+ Treg cells. We also tested in vivo the 
anti-tumour mechanism of the therapy by the administration of anti-CD4, anti-CD8, or 
anti-NK1.1 antibody, carrageenan (depletion of macrophages), or anti-IFN-γ neutralising 
antibody (Publication 3, Fig. 3C). Particularly CD8+ cells and IFN-γ, and to a lesser extent 




1826 combined with DNA vaccine. Similarly, CD8+, NK1.1+ cells and IFN-γ played anti-
tumour role in mice treated with α-GalCer combined with DNA vaccine, whereas 
macrophages did not significantly affect tumour growth.  
Previous studies have also shown cooperation between cells of innate and adaptive 
immunity and important role of CD8+ T cells and macrophages in killing of tumour cells 
(226–228). We therefore focused on CD8+ T cell activation and macrophage polarization 
in TC-1/A9 tumours. In this respect, we measured IFN-γ production, a marker of T cell 
activation, with an ELISPOT assay (Publication 3, Fig. 4A). We isolated mononuclear 
splenocytes from mice treated with DNA vaccine alone, or combined with ODN 1826, α-
GalCer and/or anti-Tim-3 monoclonal antibody and re-stimulated these mononuclear 
splenocytes with E7 (MHC-I restricted) or PADRE (MHC-II restricted) peptides. The 
treatment of mice with ODN 1826 enhanced IFN-γ production, especially in PADRE re-
stimulated cells. α-GalCer, anti-Tim-3 or the combination of adjuvants with anti-Tim-3 
did not improve the activation of splenocytes. Subsequently, we conducted flow 
cytometry analysis of  T-cell markers of activation (IFN-γ and TNF-α) and exhaustion 
(PD-1 and Tim-3) (7) in tumour infiltrating CD8+ T cells (Publication 3, Fig. 4B). 
Immunotherapy significantly induced IFN-γ production in a relatively small portion of 
CD8+ T cells, and the frequency of PD-1+ or Tim3+ CD8+ T cells in tumours was also 
significantly increased. The expression of the immune checkpoints was reduced after 
Tim-3 blockade.  
According to the previous study, M2 macrophages are the major 
immunosuppressive cells in TC-1-induced tumours (229). Macrophages are prominent 
myeloid population also in TC-1/A9-induced tumours (Publication 3, Fig. 3B). Based on 
the intensity of MHC-II expression (230), we monitored macrophage polarization into 
M1 (MHC-IIhi) and M2 (MHC-IIneg) phenotype.  M1 macrophages are also defined by 
other markers, such as iNOS and TNF-α and M2 macrophages by expression of arginase 
and urea production (230–232). MHC-IIhi M1 macrophages were markedly enriched in 
tumours of mice receiving immunotherapy, while MHC-IIneg M2 macrophages were 
abundant in tumours of non-treated mice (Publication 3, Fig. 5A). ODN 1826 combined 
with DNA vaccination significantly induced the expression of iNOS, while TNF-α 
intracellular expression was not enhanced with combined therapy (Publication 3, Fig. 
5B). TAMs were partially Tim-3+ and the immunotherapy upregulated the expression. 




phenotype. In order to further test the role of ODN 1826 and Tim-3 blockade in the 
polarization and activity of macrophages, we stimulated TAMs in vitro and used 
peritoneal macrophages as a reference. We measured production of NO (a marker of 
iNOS activity) (Publication 5, Fig. 5D) and TNF-α (Publication 5, Fig. 5E). NO and TNF-
α were significantly induced by ODN 1826 in the IFN-γ dependent manner in peritoneal 
macrophages. The NO production by TAMs corresponded to the production by peritoneal 
macrophages but ODN 1826 induced TNF-α independently of IFN-γ treatment. 
Interestingly, Tim-3 blockade did not have any effect on NO or TNF-α production. To 
assess the ability of TC-1/A9 cells to directly influence the polarization of TAMs, we co-
cultivated TAMs and TC-1/A9 cells in vitro (Publication 3, Fig. 6). We measured the 
production of NO (Publication 3, Fig. 6A) and urea (a marker of arginase activity; 
Publication 3, Fig. 6B) as markers of M1 and M2 polarization, respectively. TC-1/A9 
cells induced NO production in TAMs stimulated by ODN 1826, whereas urea production 
was independent of the stimulation. Tim-3 blockade did not have the effect neither on NO 
nor urea production. Altogether, these data indicate that TAMs in TC-1/A9-induced 
tumours can be polarized to M1 phenotype by immunotherapy. 
As the reduction of tumour growth after combined therapy was temporary, we 
assessed the immunosuppressive mechanisms of acquired resistance to combined therapy. 
With RT-qPCR, we measured expression of genes (Ifng, Ido1, Il10, Foxp3, Ncf1, Tgfb1, 
and Arg1) potentially associated with immunosuppression within the tumour 
microenvironment (Publication 3, Fig. 7). Ifng and Ido1 expression was enhanced with 
combined therapy and both markers correlated with each other, which implies the 
induction of Ido1 expression by IFN-γ in TC-1/A9-induced tumours. This observation 
further supports the dual role of IFN-γ in the tumour microenvironment (233).  
3.4. Publication 4: Establishment and characterization of mouse tumour 
cell line with irreversible downregulation of MHC class I molecules 
Heterogeneity of MHC-I expression on tumour cells regulates their oncogenicity 
and invasiveness and efficacy of immunotherapy (234). Downregulation of MHC-I 
expression is one of the most frequent mechanisms of tumour escape from immune 
surveillance and is associated with primary and acquired resistance to cancer therapy 
(122, 235). In our study, we developed a model of TC-1-derived mouse tumours with 




Firstly, we deactivated beta-2-microglobulin (B2m) in TC-1 cells with 
CRISPR/Cas9 system and established TC-1/dB2m cells with irreversible downregulation 
of MHC-I. Next, we compared in vitro characteristics of TC-1, TC-1/A9, and TC-1/dB2m 
cell lines (Publication 4, Fig. 1). Surface expression of H-2Kb, H-2Db, and B2m molecules 
was considerable on unstimulated TC-1 cells and IFN-γ even slightly upregulated the 
expression (Publication 4, Fig. 1A). Expression of these molecules on unstimulated TC-
1/A9 cells was downregulated but inducible by IFN-γ. We confirmed the abrogation of 
B2m and downregulated the surface expression of MHC-I heavy chains H-2Kb and H-
2Db on TC-1/dB2m. Although B2m is also associated with CD1d molecule (236), the 
deactivation of B2m did not affect the surface expression of CD1d. Furthermore, the 
proliferation rate of TC-1/dB2m cells was significantly reduced compared to TC-1 and 
TC-1/A9 cell lines and IFN-γ did not affect this parameter in any cell line (Publication 4, 
Fig. 1B). This observation is consistent with previous reports that showed B2m as a factor 
promoting proliferation and invasiveness of tumour cells (237, 238). 
Oncogenicity of TC-1/dB2m cells was markedly decreased in comparison with 
TC-1- and TC-1/A9-induced tumours (Publication 4, Fig. 2A). Furthermore, MHC-I 
downregulation was associated with abrogation of anti-oncogenic role of CD8+ cells, 
whereas NK1.1+ cells significantly reduced the growth of all three types of tumours 
(Publication 4, Fig. 2B). Consistently, a previous study has also shown enhanced growth 
of mouse tumours with deactivated B2m after depletion of NK1.1+ cells (239). Moreover, 
MHC-I downregulation markedly decreased sensitivity to DNA vaccination (Publication 
4, Fig. 2C). TC-1/dB2m-induced tumours did not respond to the DNA vaccine, although 
the preventive DNA vaccination completely abrogated the growth of TC-1-induced 
tumours and significantly reduced the growth of TC-1/A9-induced tumours. These data 
indicate the importance of MHC-I expression on tumour cells in the efficacy of DNA 
vaccine. In order to induce anti-cancer immune response in TC-1/dB2m-induced tumours, 
we combined DNA vaccination with adjuvants (ODN 1826 or α-GalCer; Publication 4, 
Fig. 3) successfully tested in TC-1/A9-induced tumours in the previous study (224). 
Combined therapy significantly reduced the growth of TC-1/dB2m-induced tumours, but 
this effect was weak.  
We next analysed the tumour microenvironment in TC-1/dB2m-induced tumours 
in non-treated mice and mice receiving immunotherapy (ODN 1826 alone or combined 




cells, Treg cells, and γδT cells) and myeloid (cDCs and pDCs) cells was significantly 
increased, while the frequency of NK cells and TAMs was downregulated in TC-1/dB2m-
induced tumours in comparison with TC-1- and TC-1/A9-induced tumours. The ratio of 
MHC-IIhi M1 to MHC-IIneg M2 macrophages was higher in TC-1/dB2m- than in TC-1- 
and TC-1/A9-induced tumours. Immunotherapy did not significantly alter the proportion 
of M1 and M2 macrophages in TC-1/dB2m-induced tumours, whereas we observed a 
considerable increase of M1 macrophages in TC-1/A9-induced tumours after 
immunotherapy in our previous study (224). In addition, immunotherapy increased the 
frequency of TAMs, PD-1+ TAMs, and activated PD-1+ NK and NKT cells in TC-
1/dB2m-induced tumours to the level comparable with TC-1- and TC-1/A9-induced 
tumours. 
To further examine anti-tumour effect of immunotherapy, we depleted CD4+, 
CD8+, and NK1.1+ cells, and macrophages and we neutralised IFN-γ in mice bearing TC-
1/dB2m tumours treated with DNA vaccine and ODN 1826 (Publication 4, Fig. 4D). 
Combined therapy of TC-1/dB2m-induced tumours was associated exclusively with anti-
oncogenic function of NK1.1+ cells and IFN-γ. We observed activated phenotype of both 
subpopulations of NK1.1+ cells, i.e., NK and NKT cells, with flow cytometry. However, 
α-GalCer, which can be presented on CD1d molecule and stimulate NKT cells (240), was 
less efficient than ODN 1826 in combined immunotherapy and we therefore hypothesise 
that NK cells are dominant in reactions against TC-1/dB2m-induced tumours. These data 
support the conclusion that irreversible downregulation of MHC-I inhibited the adaptive 






Despite the recent success of ICIs in cancer therapy, many patients suffer from 
primary or acquired resistance. Personalised approach in the selection of patients suitable 
for a specific type of cancer immunotherapy would prolong patients’ life expectancy, 
minimise side effects, and reduce treatment expenses. Therefore, predictive markers are 
necessary to distinguish which patients will benefit from the therapy. The objective of 
this thesis was to establish clinically relevant mouse experimental tumour models in order 
to study predictive markers for ICIs and anti-tumour immune response. 
The main project of this dissertation thesis focused on the sensitivity of tumours 
with abrogated IFN-γ signalling to PD-1/PD-L1 blockade. IFN-γ is considered to be the 
major inducer of PD-L1 and MHC-I expression (81). PD-L1 expression in tumours 
predicts sensitivity to PD-1/PD-L1 axis blockade in most cases (145). Defects in IFN-γ 
signalling or MHC-I expression have been found in some cancer patients with primary 
and acquired resistance to ICIs (122, 126). We showed that IFN-α and IFN-β induced PD-
L1 and MHC-I expression on tumour cells with abrogated IFNGR1 receptor in vitro and 
we confirmed this effect with antibody neutralizing IFN-α/IFN-β receptor in mouse 
tumours. As both the TC-1/A9- and TC-1/A9/dIfngr1-induced tumours were sensitive to 
the PD-L1 blockade combined with DNA vaccination, abrogation of IFN-γ signalling 
may not be a contraindication for PD-1/PD-L1 axis blockade. Sensitivity of tumour cells 
to type I IFNs as well as IFN-γ should be therefore evaluated as a predictive marker of 
PD-1/PD-L1 blockade.  
Efficacy of the anti-PD-L1 antibody was low in TC-1-induced tumours. Previous 
study has shown that PD-L1 blockade may promote CTLA-4/CD80 axis (133). Thus, we 
tested whether CD80 expression on tumour cells inhibits sensitivity to PD-L1 blockade 
in mice bearing TC-1-induced tumours. Although CD80 deactivation in TC-1 cells did 
not enhance the efficacy of anti-PD-L1 treatment, TC-1/dCD80-1-induced tumours were 
more immunogenic and more sensitive to anti-CTLA-4 antibody than TC-1-induced 
tumours. Analysis of the tumour microenvironment revealed that CD80 deactivation 
increased the frequency of lymphoid as well as myeloid cells infiltrating tumours. It also 
promoted M1 phenotype of macrophages and enhanced CTLA-4 expression on Th17 




marker of CTLA-4 blockade. Development of tumour cell targeted CD80 blockade 
should be considered as a novel tumour treatment. 
Next, we tested the combined therapy of tumours with reversible MHC-I 
downregulation and evaluated the efficacy of another ICI, an anti-Tim-3 antibody. In this 
study, activation of innate immune response with adjuvants (ODN 1826 and/or α-GalCer) 
promoted the efficacy of DNA vaccination, which elicited adaptive immune response and 
resulted in markedly reduced TC-1/A9-induced tumour growth. Although Tim-3 was 
expressed in the tumour microenvironment, Tim-3 blockade had a weak effect on tumour 
growth and anti-tumour immune response. The combined therapy enhanced the frequency 
of immune cells (mainly CD8+ T cells) in the tumours and induced macrophage 
polarization into M1 phenotype. We showed that activation of innate and adaptive 
immune response with combined therapy was beneficial in cancer treatment. 
Finally, we introduced a tumour model with irreversible downregulation of MHC-
I. Expression of this molecule regulated sensitivity to DNA vaccination. While TC-1-
induced tumours were sensitive to DNA vaccination, the TC-1/A9-induced tumours were 
less affected and TC-1/dB2m-induced tumours were resistant to DNA vaccination. 
Combination of DNA vaccination with the adjuvant ODN 1826 only slightly reduced TC-
1/dB2m-induced tumour growth. The combined therapy did not increase the number of 
cells infiltrating TC-1/dB2m-induced tumours. As the irreversible MHC-I 
downregulation impaired the anti-tumour effect of CD8+ T cells, NK1.1+ cells controlled 
the growth of TC-1/dB2m-induced tumours and were associated with the efficacy of the 
combined therapy.  
Taken together, this thesis contributed to the development of clinically relevant 
mouse experimental models of tumours with abrogated IFN-γ signalling or CD80 
expression, or reversible and irreversible MHC-I downregulation. We used these models 
to test the efficacy of ICIs and to study predictive biomarkers for this cancer treatment. 
Research into single predictive markers should be implemented into the “cancer 
immunograms” to select cancer patients suitable for the treatment with ICIs and to choose 
the appropriate type of this treatment. Moreover, we developed experimental combined 
therapy of tumours with reversible MHC-I downregulation, one of the most frequently 
occurring mechanism of tumour escape from immune surveillance. Our experimental 




of MHC-I expression in human tumours and may contribute to the further clinical 




5.  CONTRIBUTION TO PROJECTS/PUBLICATIONS 
5.1. Abrogation of IFN-γ signalling may not worsen sensitivity to PD-
1/PD-L1 blockade 
During my doctoral studies, I focused mainly on the sensitivity to PD-1/PD-L1 
blockade in tumours with abrogation of IFN-γ signalling. I had joined the lab when the 
cell lines with IFNGR1 deactivation have already been prepared and the oncogenicity of 
respective cell lines was evaluated. From then on, with the kind support of my supervisor, 
I acquired funding for the continuation of this project (GAUK 988218), designed and 
conducted most experiments (Publication 1, Fig. 1A, C, and D, Fig. 2-6), analysed the 
data, and wrote the original draft of the publication where I am the first author. 
5.2. CD80 expression on tumour cells alters tumour microenvironment 
and the efficacy of cancer immunotherapy by CTLA-4 blockade 
This study was the second project, where I was the first author of the respective 
publication. I designed and conducted most experiments (data presented in all figures of 
Publication 2), analysed the data, and wrote the manuscript of the publication, with the 
kind support of my supervisor and colleagues. 
5.3. Experimental combined immunotherapy of tumours with major 
histocompatibility complex class I downregulation 
In this study, I contributed to the analysis of tumour infiltrating leucocytes. I had 
the opportunity to be involved in multicolour flow cytometry experiments and the data 
analysis of lymphoid cells with FlowJo software (Publication 3, Fig. 3A, B and Fig. 4B). 
I also helped with editing of the manuscript.    
5.4. Establishment and characterization of mouse tumour cell line with 
irreversible downregulation of MHC class I molecules 
In this project, I assisted with in vitro proliferation assay (Publication 4, Fig. 1B), 
was involved in in vivo depletion experiments (Publication 4, Fig. 2B, 4D) and 
participated in the combined therapy (Publication 4, Fig. 3). Next, I was involved in 




multicolour panels of antibodies, the setup of flow cytometer, the experimental procedure, 
and data analysis with FlowJo software. I was also involved in editing of the manuscript. 
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